Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00225-X/fulltext?dgcid=hubspot_email_conferencealerts_ers24&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_tAUV50pMTsMsxyoGk11jUFKkaNuGsFFYYcqQ-znKkdBVDGbi6_yXb1Y27iklImu9Lv6gEzeVf2GvyroxNmcM7ek9-BA&_hsmi=325072833&utm_content=323935440&utm_source=hs_email